Creative Biolabs’ expanded primary neuron portfolio includes cortical, hippocampal, dopaminergic, and sensory neurons isolated and characterized under stringent quality control (QC) standards and ...
Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA ® (narsoplimab-wuug) to its distributors were completed last week, with orders from transplant ...
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — Omeros Corporation (NASDAQ: OMER) today ...
A stem cell transplant usually requires you to stay in the hospital for weeks and get frequent checkups for months after you go home. Close monitoring lets your health care team support your recovery ...
The MarketWatch News Department was not involved in the creation of this content. -- Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: ...
Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...
(RTTNews) - Omeros Corp. (OMER), a clinical-stage biopharmaceutical company focused on complement-mediated diseases, oncology, and addictive disorders, today announced its financial results for the ...
Page parent Adam Duggins talks about the fresh coat of paint on the entrance and outside at the school in Greensboro on Sept. 10. Page's courtyard has been cleared of overgrowth. Light now shines in ...
Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results